Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets

Mohammad A. Al-Mterin, Eyad Elkord*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)


Myeloid-derived suppressor cells (MDSCs) are a group of immature myeloid cells, which are expanded in most cancer patients. MDSCs suppress host immune responses, leading to cancer growth and progression. Several studies demonstrated that there was a relationship between levels of MDSCs and tumorigenesis in colorectal cancer (CRC) patients. MDSCs are now being investigated for their role as possible therapeutic targets in cancer treatment. This review summarizes available studies that investigated MDSC expansion in CRC patients, as well as their role in CRC tumorigenesis, prognosis, and targeting. Based on the available studies, there is a possible relationship between high levels of MDSCs and CRC progression. Additionally, targeting MDSCs in CRC patients selectively represents a significant challenge for the development of targeted treatments. Targeting of MDSCs could be exploited in different ways including MDSC depletion, inhibition of MDSC function and recruitment, and enhancing MDSC differentiation. Overall, MDSCs could be exploited as prognostic biomarkers and potential therapeutic targets in CRC.

Original languageEnglish
Pages (from-to)497-510
Number of pages14
JournalExploration of Targeted Anti-tumor Therapy
Issue number4
Publication statusPublished - 2022
Externally publishedYes


  • colorectal cancer
  • Myeloid-derived suppressor cells
  • prognostic biomarkers
  • targeting


Dive into the research topics of 'Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets'. Together they form a unique fingerprint.

Cite this